Investors who witnessed Moderna’s (Nasdaq: MRNA) meteoric rise during the pandemic know just how profitable new biotechnology companies can be. As a pioneer in gene-editing medicines, CRISPR Therapeutics (Nasdaq: CRSP) could be another up-and-coming biotech stock that you want to keep your eye on. In December 2023, CRISPR received approval from the FDA to treat sickle cell disease (SCD) and beta-thalassemia with its landmark drug, CASGEVY. However, despite this breakthrough, CRSP stock is down 15% in 2024.  CRISPR’s Breakthrough Treatment To start, investors should be careful buying CRSP stock as its success depends almost entirely on CASGEVY over the short term. CRISPR currently has 5 other drugs in clinical programs.…

When we first started writing about Solana, it is was trading for around $3.50 a token (it’s currently at $165). At that time, making a Solana crypto price prediction didn’t make sense yet. After all, it was pretty new back then. But still, we liked what we saw. The foundational blockchain behind Solana crypto looked strong then. And it looks even stronger now. At the time, Solana was still very much a speculative investment. But speculators who took the chance have seen a huge increase in value of Solana crypto. And this comes despite a drop-off at the end of 2021 and bear market through ’22 and ’23. However, the…